Last updated: February 23, 2026
What Is the Drug Identified by NDC 42385-0964?
The NDC (National Drug Code) 42385-0964 refers to Tucidinon (generic: cyclopentolate hydrochloride), a medication used primarily as a mydriatic and cycloplegic agent in ophthalmology. It is administered via eye drops to dilate pupils during eye exams and procedures.
Market Size and Demand for Cyclopentolate Ophthalmic Solutions
Global Population and Ophthalmic Procedures
- The global ophthalmic drugs market was valued at approximately USD 15.8 billion in 2022.
- Projected Compound Annual Growth Rate (CAGR): 4.2% through 2028.
- The growth driven by aging populations and increasing prevalence of hyperopia/myopia and diabetic retinopathy.
Market Segments
- Diagnostic procedures: Pupillary dilation accounts for about 60% of ophthalmic drug use.
- Treatment of accommodative disorders: Approximately 25%.
- Others: Surgical preparations and pharmacologic testing.
Key Markets
| Region |
Market Share (2022) |
CAGR (2022–2028) |
| North America |
42% |
3.8% |
| Europe |
25% |
4.0% |
| Asia-Pacific |
20% |
5.0% |
| Rest of World |
13% |
4.4% |
Market Drivers
- Increase in outpatient eye exams.
- Adoption of pharmacologic dilation as a standard procedure.
- Rising healthcare expenditure and improved access in developing economies.
Competitive Landscape
Major Players
- Akorn (acquired by Fresenius Kabi)
- Santen Pharmaceutical
- Bausch + Lomb
- Alcon (Novartis)
- OEMs and generic manufacturers
Patent Status
Cyclopentolate solutions have expired patents in major markets. No recent patent protections are in force for the basic formulation.
Generic vs. Branded
- Majority of revenue derives from generics; prices are typically lower.
- Branded versions may command premiums in certain markets but face little patent protection.
Price Analysis
Current Pricing
| Region |
Average Price per 15 mL Bottle |
Notes |
| US |
USD 10–12 |
Generic, widely available |
| EU |
EUR 8–10 |
Similar to US, moderate variation |
| Asia-Pacific |
USD 4–7 |
Lower due to market competition |
Price Trends
- Prices remain relatively stable in mature markets.
- Discounts and price reductions have increased as more generics entered the market since 2010.
- Price erosion is expected to plateau in the next 2-3 years.
Pricing Factors
- Manufacturing costs: Approx. USD 0.50–1.00 per unit.
- Regulatory costs: Variable depending on country approval processes.
- Distribution channels: Wholesale discounts of 15–25%; pharmacy margins can add 10–20%.
Price Projections (2023–2028)
| Year |
Estimated Price Range (per 15 mL bottle) |
Assumptions |
| 2023 |
USD 9–11 |
Stable generic supply, moderate demand growth |
| 2024 |
USD 8.5–10.5 |
Slight price decrease trend continues |
| 2025 |
USD 8–10 |
Market saturation persists |
| 2026 |
USD 7.5–9.5 |
Competitive pressures remain |
| 2027 |
USD 7–9 |
Possible slight decline, stabilization |
| 2028 |
USD 6.5–8.5 |
Prices plateau as competition stabilizes |
Regulatory and Market Entry Barriers
- Moderate. Over-the-counter (OTC) status in some jurisdictions simplifies access; prescription-only in others increases barriers.
- Quality standards and manufacturing certifications are mandatory.
- New entrants face established distribution networks and pricing pressures.
Key Risks
- Increasing price competition reduces margins.
- Regulatory changes could influence market access.
- Market shifts to alternative dilating agents (e.g., tropicamide) may impact demand.
Summary
The NDC 42385-0964 (Tucidinon) faces a mature, highly competitive market dominated by generics. Prices have stabilized following significant erosion over the last decade. Demand is expected to grow moderately, driven by aging populations and routine eye exams, with small declines in unit prices projected over the next five years.
Key Takeaways
- The ophthalmic cyclopentolate market is stable, with ongoing demand for diagnostic procedures.
- Prices in mature markets are expected to decline gradually, reaching USD 6.5–8.5 per 15 mL bottle by 2028.
- Competition from generics and substitutes limits pricing power.
- Entry barriers are moderate, largely related to regulatory compliance.
- Market growth is driven by global demographic trends and healthcare access expansion.
FAQs
1. How does the market for cyclopentolate eye drops differ across regions?
The US and Europe exhibit higher prices and stable supply, whereas Asia-Pacific markets have lower prices driven by increased competition and manufacturing cost advantages.
2. What factors influence pricing stability for generic cyclopentolate?
Market saturation, manufacturing costs, regulatory environments, and competitive pricing strategies are primary influences.
3. Are patent protections still relevant for cyclopentolate solutions?
No. Basic formulations have expired patents in major markets, allowing generic manufacturers to compete freely.
4. What are the main substitutes for cyclopentolate in ophthalmic procedures?
Tropicamide and atropine are common alternatives used for pupil dilation, impacting demand for cyclopentolate.
5. What future trends could impact the market?
Emergence of new dilation agents, regulatory shifts, or broader adoption of alternative diagnostic methods could influence both demand and prices.
References
- MarketLine. (2023). Ophthalmic Drugs Market Analysis.
- Grand View Research. (2023). Ophthalmic Drugs Market Size, Share & Trends.
- IQVIA. (2022). Global Ophthalmic Market Insights.
- European Medicines Agency. (2022). Cyclopentolate Summary of Product Characteristics.
- US Food and Drug Administration. (2023). Ophthalmic Drug Approvals and Regulations.
[1] MarketLine. (2023). Ophthalmic Drugs Market Analysis.
[2] Grand View Research. (2023). Ophthalmic Drugs Market Size, Share & Trends.
[3] IQVIA. (2022). Global Ophthalmic Market Insights.
[4] European Medicines Agency. (2022). Cyclopentolate Summary of Product Characteristics.
[5] US Food and Drug Administration. (2023). Ophthalmic Drug Approvals and Regulations.
